Pfizer to Present Data on Neratinib, Sutent at San Antonio Breast Cancer Symposium | GenomeWeb

By Turna Ray

Pfizer is planning to present new findings on several targeted oncologics at a major breast cancer conference this week, offering a peek into the company's ongoing work in cancer personalization.

At the San Antonio Breast Cancer Symposium being held Dec. 9–13, Pfizer will present new clinical trial data on neratinib, an investigational pan-ErbB inhibitor in patients with HER2-positive breast cancer, as well as data on the marketed oncologic Sutent (sunitinib malate) in metastatic breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.